Inhibrx Biosciences Inc (INBX) Stock Price, Quote & News

Company Profile

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lu...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 795 4220

Website: inhibrx.com

Address:

11025 North Torrey Pines Road, Suite 140, La Jolla, United States

DeltaVariant Jun. 5 at 3:53 PM

$INBX Starter. I'm not saying buy zone, but pretty close....Now if the market corrects that 20% everyone is expecting, then yea $68

0 · Reply

Mike22332233 Jun. 5 at 12:41 AM

$INBX $ATER $KODK $PZZA I call the kinds of stocks I uncover and invest in, like $SLS and all the others I listed in the re-post below-- Special Situation Stocks ... They could just as easily be called "wake up stocks", because there is nothing to do but HOLD ON TO THEM until you wake up one morning to great headline news and a massive upward re-pricing adjustment !!! ... FOLLOW me 👉 @Mike22332233 for all my latest Special Situation Stocks for FAST & LARGE GAINS

1 · Reply

Mike22332233 Jun. 3 at 9:45 PM

MY TOP SPECIAL SITUATION STOCK HOLDINGS & EXPECTED % RETURNS ... 1) SLS 1,650%-2,650% 2) $INBX 300%-500% 3) $ATER 100%-300% 4) $KODK 50%-100% 5) $PZZA 57%-63% 6) ZIM 43%-51% 7) WEN 40%-46% 8) MNRO 41%-45% 9) DDI 35%-52% 10) LSTA 50% 11) PRTH 21%

0 · Reply

BullStockpicks1 Jun. 3 at 7:58 AM

@Mike22332233 Mike DM me would love to discuss $INBX

0 · Reply

10xorbust Jun. 2 at 6:01 PM

$INBX $SLS I would concur that it has one of the best potential for an asymmetrical return I’ve ever seen. The length the Regal clinical trial has gone on is astonishing. AML is such a rapid, ruthless and brutal killer especially if you can’t get a stem cell transplant. The fact that this trial has gone on for six years and more than two years after the last patient was enrolled is astonishing if you know anything about AML leukemia, which unfortunately I do. No, there are no guarantees in the market, but this is about the best setup in a clinical trial I’ve ever seen. I normally don’t size up my bio investments quite this much.

0 · Reply

Mike22332233 Jun. 2 at 5:56 PM

$SLS $SLS is my #1 largest holding in a $1.4 mil portfolio, with the best asymmetrical return potential I have ever seen in my 43 years of investing… ALL profits from my Special Situation Stocks go into more SLS ... My #2 holding is $INBX ... They have 2 major assets/platforms: Ozekibart (INBX-109) which may be worth $3-$4 Bil, and INBX-106 which may be worth $5-$6 Bil ... with some people putting a much higher value on each … Here is the play on $INBX ... They will sell one of these 2 for BILLIONS and then spin off the other one (and the rest of pipeline) into a new Company .... They have done this EXACT thing in the past !!! ... Considering that INBX at $90.46 today has a market cap of $1.33 BIL, you can see how RIDICULOUSLY undervalued it is if I am correct in my analysis!!!! .... I expect sale to occur in next 1-3 months and then followed quickly with the spinoff !!! ... LIKE if you agree ... FOLLOW me @Mike22332233 for all the newest updates on my Special Situation Stocks

1 · Reply

Terzman Jun. 1 at 12:17 PM

Targeted therapy shows promise for patients with advanced colorectal cancer in a first-in-human study $INBX 👀 https://www.icr.ac.uk/about-us/icr-news/detail/targeted-therapy-shows-promise-for-patients-with-advanced-colorectal-cancer-in-a-first-in-human-study

0 · Reply

MBWallingford May. 31 at 2:43 PM

$INBX no. When a deal is close news leaks and the stock moves up. Secondary will be needed to fund testing. The molecules they have promise. Plenty of situations like that. If Merck was going to buy, it would have likely happened. A sticky point could be application. If it can help many different cancers, it maybe worth spending on testing to demonstrate value. Comes with the risk of test failure which is a reality. Take the money and sell. How many times has a stock doubled in value on a buyout deal in biotech?

0 · Reply

wall_street13 May. 29 at 12:18 PM

$INBX where is everyone... its when the chatter dies down that a deal will happen.

0 · Reply

Mongolikecandy May. 23 at 9:42 PM

$INBX Im guessing Friday's drop was related to this abstract at ASCO. https://www.fiercepharma.com/pharma/merck-kelun-sac-tmt-adc-combo-beats-keytruda-65-progression-first-line-lung-cancer Anyone have any thoughts on how INBX/Keyruda stacks up against Kelun/Keytruda treatment for nsclc?

2 · Reply

Inhibrx price target raised to $325 from $300 at Stifel

May 14, 2026, 4:02 PM EDT - 22 days ago

Inhibrx Reports First Quarter 2026 Financial Results

May 14, 2026, 7:00 AM EDT - 22 days ago

Inhibrx Biosciences Quarterly report: Q1 2026

2026-05-11T16:20:41.000Z - 25 days ago

Inhibrx’s INBRX-106 shows potential benefit in HNSCC

May 11, 2026, 8:30 AM EDT - 25 days ago

Inhibrx Biosciences Transcript: Study update

May 11, 2026, 8:30 AM EDT - 25 days ago

Inhibrx Biosciences Press release: Study update

May 11, 2026, 8:26 AM EDT - 25 days ago

This Surging Biotech Stock Shrugs Off Positive Cancer Trial Results and Slips. What to Know.

May 11, 2026, 8:00 AM EDT - 25 days ago

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

May 8, 2026, 4:00 PM EDT - 4 weeks ago

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

2026-04-24T13:35:38.000Z - 6 weeks ago

Inhibrx initiated with an Outperform at LifeSci Capital

Apr 23, 2026, 8:00 AM EDT - 6 weeks ago

Inhibrx Biosciences Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 6 weeks ago

Inhibrx Biosciences Proxy statement: Proxy filing

2026-04-22T16:50:17.000Z - 6 weeks ago

Inhibrx price target raised to $300 from $150 at Stifel

2026-04-22T14:07:06.000Z - 6 weeks ago

Inhibrx trading halted, volatility trading pause

2026-04-22T14:01:35.000Z - 6 weeks ago

Inhibrx trading resumes

2026-04-22T12:50:13.000Z - 6 weeks ago

Inhibrx’s cancer drug drawing interest from Merck, Ono, Reuters says

MRK

2026-04-22T12:49:00.000Z - 6 weeks ago

Inhibrx up 39% at $117 after report of interest from Merck in cancer assets

Apr 22, 2026, 7:02 AM EDT - 6 weeks ago

Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say

MRK

Apr 21, 2026, 4:30 PM EDT - 6 weeks ago

Inhibrx Biosciences Transcript: Study update

Apr 21, 2026, 4:30 PM EDT - 6 weeks ago

Inhibrx Biosciences Press release: Study update

2026-04-21T20:24:03.000Z - 6 weeks ago

Inhibrx reports interim data from its Phase 1/2 study evaluating ozekibart

Apr 21, 2026, 4:05 PM EDT - 6 weeks ago

Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

Apr 21, 2026, 7:00 AM EDT - 6 weeks ago

Inhibrx Biosciences Slides: Investor presentation

Apr 20, 2026, 5:03 PM EDT - 6 weeks ago

Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

2026-04-07T20:17:46.000Z - 2 months ago

Inhibrx initiated with a Buy at Stifel

Mar 19, 2026, 6:00 PM EDT - 2 months ago

Inhibrx Biosciences Earnings release: Q4 2025

Mar 19, 2026, 6:00 PM EDT - 2 months ago

Inhibrx Biosciences Annual report: Q4 2025

2026-03-19T20:10:58.000Z - 2 months ago

Inhibrx reports Q4 EPS ($2.11) vs. ($3.09) last year

Mar 19, 2026, 4:00 PM EDT - 2 months ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Mar 12, 2026, 7:00 AM EDT - 3 months ago

Inhibrx Biosciences Slides: Investor presentation

Mar 2, 2026, 4:00 PM EST - 3 months ago

Inhibrx Announces Participation in Upcoming Scientific Conference

Jan 22, 2026, 10:26 AM EST - 4 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE KOD LITE

2025-12-16T22:10:33.000Z - 6 months ago

Inhibrx provides update on INBRX-106 Phase 2/3 clinical trial

Dec 16, 2025, 5:00 PM EST - 6 months ago

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

Nov 14, 2025, 6:00 AM EST - 7 months ago

Inhibrx Reports Third Quarter 2025 Financial Results

Nov 13, 2025, 6:00 PM EST - 7 months ago

Inhibrx Biosciences Quarterly report: Q3 2025

Nov 13, 2025, 6:00 PM EST - 7 months ago

Inhibrx Biosciences Earnings release: Q3 2025

Nov 4, 2025, 4:01 PM EST - 7 months ago

Inhibrx Announces Participation in Upcoming Scientific Conferences

2025-10-24T09:55:27.000Z - 8 months ago

Why Is Inhibrx Biosciences Stock (INBX) Surging Today?

Oct 23, 2025, 6:39 PM EDT - 8 months ago

Inhibrx shares surge after bone cancer drug slows disease progression in trial

2025-10-23T20:45:32.000Z - 8 months ago

Inhibrx trading resumes

Oct 23, 2025, 4:30 PM EDT - 8 months ago

Inhibrx Biosciences Transcript: Study Result

Oct 23, 2025, 4:30 PM EDT - 8 months ago

Inhibrx Biosciences Press release: Study Result

Oct 23, 2025, 4:05 PM EDT - 8 months ago

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Oct 22, 2025, 4:01 PM EDT - 8 months ago

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Aug 13, 2025, 4:05 PM EDT - 10 months ago

Inhibrx Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 6:00 PM EDT - 10 months ago

Inhibrx Biosciences Quarterly report: Q2 2025

Aug 12, 2025, 6:00 PM EDT - 10 months ago

Inhibrx Biosciences Earnings release: Q2 2025

May 14, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Reports First Quarter 2025 Financial Results

May 14, 2025, 8:00 AM EDT - 1 year ago

Inhibrx Biosciences Quarterly report: Q1 2025

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Inhibrx Biosciences Proxy statement: Proxy filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Inhibrx Biosciences Proxy statement: Proxy filing

Apr 1, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

Mar 17, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Mar 16, 2025, 7:00 PM EDT - 1 year ago

Inhibrx Biosciences Earnings release: Q4 2024

Mar 16, 2025, 7:00 PM EDT - 1 year ago

Inhibrx Biosciences Annual report: Q4 2024

Jan 21, 2025, 5:01 PM EST - 1 year ago

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Jan 13, 2025, 4:15 PM EST - 1 year ago

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Nov 14, 2024, 4:24 PM EST - 1 year ago

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 7:00 AM EST - 1 year ago

Inhibrx Biosciences Quarterly report: Q3 2024

Nov 4, 2024, 4:00 PM EST - 1 year ago

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Aug 13, 2024, 6:54 PM EDT - 1 year ago

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Inhibrx Biosciences Quarterly report: Q2 2024

Jun 11, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Registration statement: Registration filing

May 24, 2024, 4:00 PM EDT - 2 years ago

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

May 21, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

May 17, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

May 10, 2024, 6:36 PM EDT - 2 years ago

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

May 9, 2024, 3:36 PM EDT - 2 years ago

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

SNY

May 8, 2024, 4:37 PM EDT - 2 years ago

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Feb 29, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Feb 28, 2024, 9:15 AM EST - 2 years ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Feb 28, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Annual report: Q4 2023

Feb 6, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Jan 23, 2024, 11:45 AM EST - 2 years ago

Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline

SNY

Jan 23, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Jan 23, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Jan 23, 2024, 5:39 AM EST - 2 years ago

Sanofi to Buy Rare-Disease Assets From Inhibrx

SNY

Jan 23, 2024, 1:32 AM EST - 2 years ago

France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln

SNY

Jan 23, 2024, 1:30 AM EST - 2 years ago

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

SNY

Jan 23, 2024, 1:00 AM EST - 2 years ago

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

SNY

Nov 9, 2023, 4:00 PM EST - 2 years ago

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 2, 2023, 9:15 AM EDT - 2 years ago

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Sep 19, 2023, 4:00 PM EDT - 2 years ago

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

Sep 1, 2023, 4:26 PM EDT - 3 years ago

Andreas Halvorsen's Firm Ups Inhibrx Stake

Aug 29, 2023, 9:00 AM EDT - 3 years ago

Inhibrx Announces $200 Million Private Placement Financing

Aug 7, 2023, 4:00 PM EDT - 3 years ago

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

May 30, 2023, 9:00 AM EDT - 3 years ago

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

May 8, 2023, 4:05 PM EDT - 3 years ago

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Apr 26, 2023, 9:00 AM EDT - 3 years ago

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

Apr 13, 2023, 8:00 AM EDT - 3 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Apr 13, 2023, 8:00 AM EDT - 3 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Mar 6, 2023, 4:05 PM EST - 3 years ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Mar 6, 2023, 7:00 AM EST - 3 years ago

Inhibrx Biosciences Annual report: Q4 2022

Jan 4, 2023, 9:00 AM EST - 3 years ago

NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates

Nov 18, 2022, 4:05 PM EST - 3 years ago

Inhibrx Announces Participation in Upcoming Investor Conference

Nov 16, 2022, 9:00 AM EST - 3 years ago

Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma

DeltaVariant Jun. 5 at 3:53 PM

$INBX Starter. I'm not saying buy zone, but pretty close....Now if the market corrects that 20% everyone is expecting, then yea $68

0 · Reply

Mike22332233 Jun. 5 at 12:41 AM

1 · Reply

Mike22332233 Jun. 3 at 9:45 PM

0 · Reply

BullStockpicks1 Jun. 3 at 7:58 AM

@Mike22332233 Mike DM me would love to discuss $INBX

0 · Reply

10xorbust Jun. 2 at 6:01 PM

0 · Reply

Mike22332233 Jun. 2 at 5:56 PM

1 · Reply

Terzman Jun. 1 at 12:17 PM

0 · Reply

MBWallingford May. 31 at 2:43 PM

0 · Reply

wall_street13 May. 29 at 12:18 PM

$INBX where is everyone... its when the chatter dies down that a deal will happen.

0 · Reply

Mongolikecandy May. 23 at 9:42 PM

2 · Reply

BullStockpicks1 May. 23 at 1:34 AM

$INBX https://x.com/bullstkpicks/status/2057997697097867490?s=46&t=cyjtCnUcMDe5-ZCjxf5y_w See my post with an update

0 · Reply

Stacks_Edwards May. 22 at 7:57 PM

$INBX to be fair, you said you bought a few hundred shares as a gamble. Why the crying now?

1 · Reply

cubie May. 22 at 7:51 PM

$INBX

0 · Reply

judgeyoung2 May. 22 at 7:50 PM

$INBX @cubie any interesting flow ?

1 · Reply

MBWallingford May. 22 at 7:39 PM

$INBX wtf. This thing is a fucking turd

0 · Reply

MBWallingford May. 22 at 3:02 PM

$INBX Merck is going up and this going down. Not the only company partnering with Merck to improve Keytruda.

0 · Reply

Mike22332233 May. 19 at 4:33 PM

$WEN The deal on $WEN is getting very very close !!!! ... Also, there will be deals on $SLS and on $INBX ... FOLLOW me 👉 @Mike22332233 as I uncover and post Special Situation Stocks that have potential HUGE & QUICK profits ahead!!!

0 · Reply

Terzman May. 19 at 11:54 AM

$INBX agreed 100% 109 gonna find a forever home like 101 did and fresh cash prob to support 106 .. which will be a mothr load return .. then what else do they have hiding in back wings ? 🤔 gotta be some crumbs of whats lurking deep on the bench .. ney net upside adds up and up imo 109 min 2x 106 gives us another 2-3x plus the unknown crumbs ..

0 · Reply

justiceforb_85 May. 17 at 1:26 AM

$INBX reasonable r/r at these levels based on ozekibart and INBRX-106.

0 · Reply

Terzman May. 15 at 2:20 PM

$INBX zero raises on horizon imho .. this is solid buy here do your dd

0 · Reply

BullStockpicks1 May. 15 at 10:05 AM

$INBX Stifel increases their PT to $325. It’s still very conservative by its own admission. With 109 approval by year end in Chomdro and likely AA in Ewings the company will be near a cash flow breakeven. I still expect them to sell 109 and spin 106 and other assets into a new spinCo like they did in early 2025 with their last drug. 109 alone can fetch $200 ish a share plus CVR for further payouts with CRC approvals. 106 is worth a lot more if PFS / OS is strong at ESMO in October

3 · Reply

focafoca99 May. 14 at 8:11 PM

$INBX released its Q1 2026 financial results for the quarter ended March 31, 2026.

0 · Reply

Market Cap	1.40B
Revenue (ttm)	1.30M
Net Income (ttm)	-140.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-10,773.85%
Debt to Equity Ratio	-8.32

Volume	417,400
Avg Vol	468,254
Day's Range	N/A - N/A
Shares Out	14.67M
Stochastic %K	7%
Beta	3.31
Analysts	Sell
Price Target	$277.50